New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...

“EFFISAYIL™ 2 is the first and largest multinational randomized clinical trial to evaluate a treatment for the prevention of GPP flares,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, ...

PP affects men and women in a ratio of 4:1. 2 Most severe infections occur in the elderly. Risk factors include tinea pedis; diabetes mellitus; hyperhidrosis; excessive participation in water sports; ...

Gram-negative folliculitis (GNF) is one of the most common mimics and complications of acne and acne rosacea. First described by Fulton in 1968, 1 GNF in acne patients is a relatively rare ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

Imsidolimab is an investigational humanized IgG4 antibody that inhibits the function of the interleukin-36 receptor. Findings from two phase 3 trials showed skin clearance was achieved and maintained ...

Erosive pustular dermatosis (EPD) is a chronic inflammatory skin disorder predominantly affecting the scalp of older individuals, often in areas of pre-existing actinic damage and androgenetic ...

AnaptysBio Inc ANAB released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. During a GPP flare, ...